Give us a call
Thank you for your interest in CSL Behring. We care about your questions and concerns. You can find the best way to contact us from the list below.
For General Questions
CSL Behring Global Headquarters
Phone: +1 610-878-4000
Fax: +1 610-878-4009
1020 First Avenue
King of Prussia, PA 19406-0901 USA
MON - FRI: 7:30 a.m. - 4:30 p.m. EST
HEALTHCARE PROVIDERS / MEDICAL PROFESSIONALS
U.S. Medical Information
MON - FRI: 9AM - 5PM ET
Medical Information Outside the U.S.
Please use local, in-country CSL Behring websites to contact us.
Clinical Trial Inquiry
Obtain more information about any of our current or prior clinical trials by emailing CSL Behring at firstname.lastname@example.org. For studies registered on ClinicalTrials.gov, the appropriate email is included in the study registration.
REPORT AN UNDESIRABLE EFFECT
In the U.S. (including Puerto Rico)
Outside the U.S.
For all others, please use your local CSL Behring website to report an event.
You are also encouraged to report negative side effects of prescription drugs to the Food and Drug Administration.
Bernard Ronchi (based in Melbourne, Australia)
Phone: +61 3 9389 3470
CSL Behring Brochure
See how we are Driven by Our Promise in our 16-page Corporate Brochure.
CSL Behring Fact Sheet
Learn about our company at-a-glance using this CSL Behring Fact Sheet.
U.S. Customer Service
For product orders and support to U.S. customers.
Customer Service Outside the U.S.
Please use your local, in-country CSL Behring website to place an order.
Human Serum Albumin (HSA) Excipient Inquiries
If you would like more information on purchasing Albumin for Excipient use, please click on the link below.
Thrombin & Fibrinogen Inquiries
If you would like more information on purchasing fibrinogen and/or thrombin for further manufacturing use, please click on the link below.
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.
Headquartered in Melbourne, Australia, CSL Limited includes: CSL Behring, incorporating CSL Plasma, and Seqirus, incorporating immunohematology.